Literature DB >> 20981118

Chronic kidney disease: implications of the AURORA and JUPITER results.

Theodoros I Kassimatis, Athanasios Agrafiotis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981118     DOI： 10.1038/nrneph.2010.126

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  New hope for chronic kidney disease patients after the JUPITER trial: myth or reality?

Authors:  Theodoros I Kassimatis; David J A Goldsmith
Journal:  J Am Coll Cardiol       Date:  2010-08-03       Impact factor: 24.094

2.  Sunset for statins after AURORA?

Authors:  Giovanni F M Strippoli; Jonathan C Craig
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

3.  Rosuvastatin in patients undergoing hemodialysis.

Authors:  Theodoros I Kassimatis; Panagiotis A Konstantinopoulos
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

4.  Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.

Authors:  Paul M Ridker; Jean MacFadyen; Michael Cressman; Robert J Glynn
Journal:  J Am Coll Cardiol       Date:  2010-03-04       Impact factor: 24.094

5.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 6.  The role of statins in chronic kidney disease (CKD): friend or foe?

Authors:  Theodoros I Kassimatis; Panagiotis A Konstantinopoulos
Journal:  Pharmacol Ther       Date:  2009-04-05       Impact factor: 12.310

Review 7.  Study of Heart and Renal Protection (SHARP).

Authors:  Colin Baigent; Martin Landry
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

Review 8.  HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Authors:  Sankar D Navaneethan; Francesca Pansini; Vlado Perkovic; Carlo Manno; Fabio Pellegrini; David W Johnson; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

9.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Authors:  Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.